Marksans Pharma Limited

NSE: MARKSANS · Healthcare

₹303.70-3.20%06 Nov 2026

Ask the data

Instant answers about Marksans Pharma Limited — computed from its filings, no language model

Market cap₹13,762 cr

Current price₹303.70

High / Low₹348 / ₹157

P/E24.6

P/B4.13

Book value₹73.5

ROE16.8%

ROCE23.1%

Debt / equity0.01

Dividend yield0.26%

EPS (TTM)₹12.35

Face value₹1

Price & valuation

split & bonus adjusted · pick a metric and range

Annual performance

annual · ₹ crore · line = operating margin

showing latest 6 of 9 periods

	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26
Revenue	767	1,000	1,134	1,376	1,491	1,852	2,177	262	2,951
EBITDA	45	132	192	340	259	339	459	53	601
Operating margin	5.8%	13.2%	17.0%	24.7%	17.4%	18.3%	21.1%	20.2%	20.4%
Interest	7	10	9	8	8	9	11	1	24
Depreciation	30	23	27	36	45	52	74	8	99
Profit before tax	15	104	157	302	248	338	424	50	561
Tax	4	24	36	64	61	72	109	12	140
Net profit	11	76	121	239	187	265	343	0	418
EPS ₹	0.22	1.87	2.86	5.76	4.51	6.41	6.92	8.40	9.22
Operating cash flow	—	—	—	—	99	237	230	21	458
Capex	—	—	—	—	46	54	209	17	131
Dividend paid	—	—	—	—	11	10	23	3	36
Total assets	—	—	—	—	—	2,190	2,681	324	3,861
Equity	—	—	—	—	—	1,745	2,065	247	3,023

Quarterly performance

last 35 quarters · ₹ crore

showing latest 8 of 35 periods

	MAR '18	JUN '18	SEP '18	DEC '18	MAR '19	JUN '19	SEP '19	DEC '19	MAR '20	JUN '20	SEP '20	DEC '20	MAR '21	JUN '21	SEP '21	DEC '21	MAR '22	JUN '22	SEP '22	DEC '22	MAR '23	JUN '23	SEP '23	DEC '23	MAR '24	JUN '24	SEP '24	DEC '24	MAR '25	JUN '25	SEP '25	DEC '25	MAR '26	JUN '26	SEP '26
Revenue	913	235	269	248	247	245	256	288	335	331	356	358	330	349	361	363	418	434	453	480	486	500	531	586	560	591	642	682	71	620	720	754	856	841	940
Operating profit	86	35	37	36	16	32	34	47	69	70	83	91	95	77	60	58	64	73	80	77	110	102	114	133	110	128	136	139	13	100	144	161	195	213	214
Operating margin	9.5%	15.1%	13.8%	14.6%	6.3%	13.2%	13.1%	16.4%	20.6%	21.1%	23.3%	25.4%	28.9%	22.2%	16.6%	15.9%	15.2%	16.8%	17.7%	16.0%	22.5%	20.4%	21.4%	22.7%	19.6%	21.7%	21.1%	20.4%	17.8%	16.1%	20.1%	21.3%	22.8%	25.3%	22.8%
Other income	0	3	-1	0	10	2	8	0	0	0	4	-3	6	6	9	12	15	16	14	18	11	10	19	5	17	15	11	28	2	6	22	20	35	25	18
Interest	10	2	3	2	2	2	3	2	2	2	2	2	3	1	2	1	5	2	3	2	2	2	2	3	5	3	3	3	0	6	6	6	6	7	7
Depreciation	27	6	6	5	6	5	5	7	10	7	19	9	1	7	7	9	21	11	14	13	14	14	18	22	21	20	20	21	2	23	27	24	24	25	32
Profit before tax	50	30	28	30	17	28	34	38	58	61	66	78	97	75	60	60	53	76	78	79	104	97	114	113	100	120	125	143	12	77	133	151	200	207	194
Tax	14	5	7	4	7	5	8	9	15	12	15	19	18	12	13	12	23	16	18	17	21	26	30	30	23	31	27	38	3	18	34	37	51	47	50
Net profit	36	25	21	25	9	21	26	0	43	49	51	59	80	0	46	48	30	60	61	63	83	69	84	83	73	89	97	105	0	58	98	113	148	157	141
EPS ₹	0.80	0.58	0.48	0.60	0.21	0.52	0.63	0.71	1.00	1.20	1.21	1.42	1.93	1.51	1.11	1.20	0.69	1.46	1.52	1.56	1.97	1.52	1.84	1.84	1.73	1.96	2.13	2.31	2.00	1.29	2.17	2.50	3.27	3.47	3.12
Revenue YoY	—	—	—	—	-72.9%	4.2%	-4.7%	15.8%	35.5%	35.1%	39.0%	24.6%	-1.5%	5.4%	1.3%	1.2%	26.6%	24.3%	25.3%	32.3%	16.3%	15.3%	17.4%	22.2%	15.2%	18.1%	20.8%	16.3%	-87.3%	5.0%	12.2%	10.6%	1108.3%	35.6%	30.5%
Profit YoY	—	—	—	—	-76.2%	-14.3%	26.3%	-100.0%	402.2%	131.7%	95.3%	—	86.0%	-100.0%	-8.8%	-18.1%	-62.7%	—	32.3%	31.4%	179.0%	15.0%	36.4%	31.3%	-12.2%	29.3%	15.8%	25.6%	-100.0%	-34.3%	1.6%	8.3%	—	169.5%	43.8%

Earlier results (standalone, Sep '07 – Dec '17)

₹ crore · from BSE, before the NSE XBRL filings begin

Marksans Pharma Limited reports consolidated figures above. Quarterly consolidated results only became mandatory in India in 2019, so the earlier history available is the standalone company only (excluding subsidiaries). It is shown separately so the two bases are never mixed.

Full years

	FY10†	FY12†	FY13†	FY14†	FY15†	FY16†	FY17†
Revenue	207	157	196	318	409	367	223
Operating profit	30	-153	48	82	119	113	31
Operating margin	14.3%	-97.6%	24.7%	25.7%	29.1%	30.7%	13.9%
Interest	19	12	10	10	13	6	3
Depreciation	10	18	9	9	9	15	15
Profit before tax	1	-183	30	63	97	92	13
Tax	1	-2	-10	8	30	20	0
Net profit	-1	-181	40	56	67	71	12

Quarters

showing latest 8 of 40 periods

	SEP '07†	DEC '07†	MAR '08†	JUN '08†	SEP '08†	DEC '08†	JUN '09†	SEP '09†	DEC '09†	MAR '10†	JUN '10†	SEP '10†	DEC '10†	JUN '11†	SEP '11†	DEC '11†	MAR '12†	JUN '12†	SEP '12†	DEC '12†	MAR '13†	JUN '13†	SEP '13†	DEC '13†	MAR '14†	JUN '14†	SEP '14†	DEC '14†	MAR '15†	JUN '15†	SEP '15†	DEC '15†	MAR '16†	JUN '16†	SEP '16†	DEC '16†	MAR '17†	JUN '17†	SEP '17†	DEC '17†
Revenue	54	58	83	54	68	51	46	40	64	57	42	45	35	33	51	31	42	38	50	50	58	75	79	81	84	101	108	106	95	105	117	69	76	42	62	65	54	52	75	80
Operating profit	7	12	11	13	15	5	3	4	10	13	8	9	1	5	15	-57	-116	-15	19	13	32	22	25	22	14	30	33	36	21	39	41	19	14	5	6	16	4	8	6	12
Operating margin	13.2%	20.0%	13.8%	23.5%	22.0%	9.5%	7.2%	9.2%	15.2%	22.8%	18.1%	19.1%	1.8%	16.3%	29.3%	-180.1%	-279.8%	-39.6%	37.5%	25.3%	55.1%	28.9%	31.2%	27.4%	16.1%	29.6%	30.3%	33.7%	21.9%	37.4%	35.0%	27.1%	18.0%	12.7%	9.5%	24.2%	7.4%	15.0%	8.4%	14.4%
Other income	2	2	1	0	1	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	0	0	—	—
Interest	4	3	4	3	5	3	4	5	5	5	4	5	4	3	3	3	3	2	2	2	3	2	3	2	3	3	4	5	2	2	2	1	1	1	1	1	1	1	2	1
Depreciation	2	2	2	2	2	2	2	2	2	2	2	1	1	3	14	1	0	2	2	2	2	2	2	2	2	2	2	2	2	3	4	4	4	4	4	4	4	4	3	3
Profit before tax	4	8	6	8	8	0	-3	-4	2	5	1	2	-4	-0	-2	-61	-120	-20	14	8	27	17	20	18	8	25	27	28	17	34	36	13	8	1	2	11	-1	3	1	8
Tax	0	1	1	1	1	0	0	-0	1	0	0	81	-2	0	0	0	-2	0	0	0	-10	0	2	2	3	7	7	12	5	10	7	-1	3	0	-1	2	-1	2	-1	2
Net profit	3	7	5	7	7	0	-3	-4	1	5	1	-79	-2	-0	-2	-61	-118	-20	14	8	37	17	18	16	5	18	20	17	12	24	29	14	5	1	3	8	1	1	1	6
EPS ₹	0.97	1.95	0.13	0.19	0.19	0.01	-0.09	-0.10	0.03	0.14	0.03	-2.15	-0.06	-0.01	-0.06	-1.65	-3.21	-0.54	0.39	0.21	0.96	0.44	0.46	0.41	0.14	0.47	0.52	0.43	0.30	0.58	0.70	0.34	0.12	0.02	0.06	0.21	0.01	0.03	0.03	0.14
Revenue YoY	—	—	—	—	25.3%	-12.7%	-15.3%	-40.6%	25.4%	—	-8.2%	10.7%	-44.6%	-21.5%	12.7%	-10.9%	—	15.8%	-0.5%	57.6%	40.5%	95.4%	56.1%	63.0%	44.2%	34.7%	37.0%	30.8%	12.5%	3.9%	8.9%	-34.4%	-20.0%	-60.1%	-46.9%	-6.8%	-28.8%	25.4%	21.2%	23.9%
Profit YoY	—	—	—	—	99.4%	-97.4%	-150.8%	-150.7%	527.8%	—	—	—	-283.2%	-124.8%	—	—	—	—	—	—	—	—	23.6%	98.5%	-85.7%	8.8%	12.5%	5.4%	132.7%	30.8%	42.6%	-15.3%	-58.7%	-97.3%	-91.0%	-39.7%	-88.8%	78.5%	-48.6%	-33.4%

Returns & margins

trailing-twelve-month, per quarter

showing latest 8 of 32 periods

	DEC '18	MAR '19	JUN '19	SEP '19	DEC '19	MAR '20	JUN '20	SEP '20	DEC '20	MAR '21	JUN '21	SEP '21	DEC '21	MAR '22	JUN '22	SEP '22	DEC '22	MAR '23	JUN '23	SEP '23	DEC '23	MAR '24	JUN '24	SEP '24	DEC '24	MAR '25	JUN '25	SEP '25	DEC '25	MAR '26	JUN '26	SEP '26
ROE	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	15.7%	16.9%	15.3%	15.8%	15.9%	17.0%	14.9%	15.9%	15.0%	15.9%	117.6%	105.2%	9.7%	10.0%	13.8%	17.1%	16.8%
ROCE	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	21.3%	22.9%	19.4%	20.5%	21.0%	22.8%	20.8%	21.9%	20.4%	21.7%	163.9%	147.7%	14.0%	14.4%	19.2%	23.4%	23.1%
Net margin	6.4%	7.9%	7.5%	8.1%	5.4%	8.0%	9.8%	10.9%	14.6%	17.3%	13.6%	13.2%	12.4%	8.3%	11.7%	11.9%	12.0%	14.4%	14.4%	14.9%	15.1%	14.1%	14.5%	14.4%	14.7%	14.6%	12.9%	12.5%	12.5%	14.2%	16.3%	16.5%
EBITDA margin	11.7%	12.4%	12.0%	11.8%	12.4%	16.2%	18.2%	20.6%	22.7%	24.7%	24.9%	23.2%	20.7%	17.4%	16.1%	16.5%	16.4%	18.3%	19.2%	20.1%	21.8%	21.1%	21.4%	21.3%	20.7%	20.9%	19.2%	18.9%	19.3%	20.4%	22.5%	23.1%
Debt / equity	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	0.03	0.03	0.02	0.02	0.02	0.02	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01
Interest coverage	8.88	11.80	11.68	12.61	13.71	18.96	24.72	32.13	37.46	38.82	43.58	45.33	47.74	30.29	27.85	26.89	25.41	37.98	41.18	50.25	49.52	38.78	36.60	34.77	38.38	47.67	31.41	25.48	21.49	24.23	28.55	29.80
Asset turnover	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	1.00	1.07	0.85	0.88	0.86	0.91	0.81	0.85	0.82	0.85	6.13	6.22	0.61	0.63	0.76	0.82	0.78

Balance sheet

equity vs borrowings over time · ₹ crore

showing latest 6 of 9 periods

	SEP '22	MAR '23	SEP '23	MAR '24	SEP '24	MAR '25	SEP '25	MAR '26	SEP '26
Share capital	40	45	45	45	45	5	45	45	45
Other equity / reserves	1,223	1,700	1,830	2,020	2,236	242	2,643	2,978	3,287
Total equity	1,263	1,745	1,876	2,065	2,281	247	2,688	3,023	3,332
Borrowings	39	42	35	29	24	2	23	30	29
Current liabilities	321	341	333	390	444	48	455	527	600
Non-current liabilities	64	84	84	205	162	27	274	281	392
Total assets	1,668	2,190	2,314	2,681	2,911	324	3,442	3,861	4,360
Property, plant & equipment	331	380	452	676	675	58	916	625	1,054
Capital work-in-progress	1	7	19	5	11	1	7	15	5
Investments	0	1	1	27	15	0	1	0	62
Inventories	428	485	531	618	758	85	955	972	996
Receivables	406	417	450	453	552	54	603	645	757
Cash & equivalents	245	382	358	403	381	50	482	634	742

Cash flow

annual · ₹ crore · line = free cash flow

	FY22	FY23	FY24	FY25	FY26
Cash from operations	99	237	230	21	458
Cash from investing	-42	-259	-141	-5	-248
Cash from financing	80	198	-69	-7	-71
Capex	46	54	209	17	131
Free cash flow	53	184	22	3	328
Dividends paid	11	10	23	3	36

Where the assets sit

Sep '26 · ₹ crore

Fixed assets (PPE)

₹1,054 cr24%

CWIP

₹5 cr0%

Investments

₹62 cr1%

Inventories

₹996 cr23%

Receivables

₹757 cr17%

Cash & equivalents

₹742 cr17%

Other assets

₹743 cr17%

Peer comparison

largest in Healthcare · this company in bold

Company	Market cap ₹cr	Price	P/E	P/B	ROE
Sun Pharmaceutical Industries Ltd.	4,46,270	1,860.00	40.7	5.00	12.3%
Divi's Laboratories Ltd.	2,73,493	10,320.50	93.5	16.32	17.5%
Torrent Pharmaceuticals Ltd.	1,80,671	4,750.00	85.1	9.83	11.6%
Laurus Labs Ltd.	1,26,430	2,340.00	94.4	20.86	22.1%
Apollo Hospitals Enterprise Ltd.	1,21,453	8,446.00	54.2	11.45	21.1%
Zydus Lifesciences Ltd.	1,19,550	1,197.90	28.6	4.30	15.0%
Dr. Reddy's Laboratories Ltd.	1,14,646	1,373.00	40.9	2.95	7.2%
Cipla Ltd.	1,13,988	1,411.00	39.3	3.22	8.2%
Mankind Pharma Ltd.	1,04,902	2,540.00	46.7	5.97	12.8%
Aurobindo Pharma Ltd.	1,03,572	1,800.00	26.0	2.63	10.1%
Marksans Pharma Limited	13,762	303.70	24.6	4.13	16.8%

StoxGud checklist: Bullish setup · 9/10

Price above 50-day average
Price above 200-day average
50-day average above 200-day (uptrend)
RSI in healthy 40–70 zone
Positive 1-year return
Return on equity above 15%
Debt to equity below 1
Revenue growing year on year
Net profit margin above 10%
P/E below industry median

A rules-based screen of trend, momentum, quality and valuation. Educational only — not a buy or sell recommendation.

Returns & technicals

1 month-6.7%

6 months+49.6%

1 year+65.3%

3Y CAGR+37.4%

5Y CAGR+35.6%

10Y CAGR+20.4%

50-day avg₹319.71

200-day avg₹243.26

RSI (14)47

FAQs

What is the share price of Marksans Pharma Limited?

Marksans Pharma Limited (MARKSANS) closed at ₹303.70 on NSE on 06 Nov 2026.

What is the market cap of Marksans Pharma Limited?

₹13,762 crore at the latest close.

What is the P/E ratio of Marksans Pharma Limited?

24.6, on trailing-twelve-month earnings from its filings.

How fast is Marksans Pharma Limited growing?

Marksans Pharma Limited: revenue has compounded at 16.8% a year over three years; net profit at 16.4% a year. Latest-quarter revenue is up 30.5% year on year, profit up 43.8%.

How profitable is Marksans Pharma Limited?

On a trailing-twelve-month basis return on equity is 16.8%, return on capital employed 23.1%, operating margin 23.1%, net margin 16.5%.

How much debt does Marksans Pharma Limited have?

Marksans Pharma Limited is debt-free: debt to equity is 0.01 with borrowings of ₹29 cr against cash of ₹742 cr (balance sheet of 2026-09-30). Operating profit covers interest 29.8 times.

Financials parsed from Marksans Pharma Limited's own XBRL filings to NSE (consolidated), ₹ crore unless marked. Quarterly from MAR '18, annual from FY18, balance sheet from Sep '22. * = derived (full year or half year minus earlier quarters). Information only, not investment advice.